A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
We are working to understand if an investigational drug could be sage and potentially effective in promoting the repair of damaged tissue in the brain and spinal cord caused by MS, possibly impacting motor function.
If you qualify and decide to take part, your total time would be about 17 visits over about 19 months. What happens each visit will vary, but may include blood and urine samples, MRI scans and questionnaires.
- IRB Number: 1810753783 (NEUR-ABBVIE-M18-918)
- Research Study Identifier: TX10376
- Principal Investigator: Jaison Grimes, MD